Romyelocel-L

Drug Profile

Romyelocel-L

Alternative Names: CLT-008; hMPC - Cellerant Therapeutics; Human myeloid progenitor cells - Cellerant Therapeutics

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellerant Therapeutics
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 08 Feb 2017 Phase-I development for Neutropenia (in patients undergoing cord blood transplantation) has been completed and preclinical development for Neutropenia (in acute radiation syndrome) is ongoing in USA
  • 08 Feb 2017 Romyelocel-L is still in phase II trials for Neutropenia (Chemotherapy-induced, in patients with acute myeloid leukaemia) in USA
  • 01 Dec 2014 Phase-II clinical trials in Neutropenia (Chemotherapy-induced) in USA (IV) (NCT02282215)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top